New pill XTYW007 enters human testing for fatty liver

NCT ID NCT07407634

Not yet recruiting Disease control Sponsor: Xi'an Xintong Pharmaceutical Research Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new drug called XTYW007 in healthy volunteers and people with high LDL cholesterol. The main goal is to check the drug's safety and how the body processes it, not yet to see if it treats non-alcoholic fatty liver disease (NAFLD). The study will involve 94 participants and includes both single and multiple doses, as well as looking at the effect of food on the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XTYW007 capsules
What this could lead to: If this early trial shows XTYW007 is safe and well-tolerated, it could pave the way for larger studies to see if it helps control non-alcoholic fatty liver disease.
What could go wrong: This is a very early (Phase I/IIa) trial with only 94 participants, focused on safety and dosing, not on whether the drug actually works. Many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Locations

The First Hospital of Jilin University

Jilin City, Changchun, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.